About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker XNCR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026Study of XmAb412 in Healthy Participants
NCT07713485 · Not Applicable - Healthy Adult Participants
XmAb412 Monoclonal Bispecific Antibody, Placebo
XNCR
Xencor, Inc.
Phase 1Recruiting128Aug 2027Registry ↗
Oct 30, 2026Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990 · Ulcerative Colitis (UC)
XmAb942, Placebo
XNCR
Xencor, Inc.
Phase 1/2Recruiting270Dec 2027Registry ↗
Oct 9, 2026Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491 · Ovarian Cancer, Endometrial Cancer
XmAb541
XNCR
Xencor, Inc.
Phase 1Recruiting282Dec 2027Registry ↗
Aug 13, 2026Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
NCT07593092 · Ovarian Cancer
XmAb541, XmAb808
XNCR
Xencor, Inc.
Phase 1Recruiting90Dec 2028Registry ↗
Aug 3, 2026A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimm…
NCT07284797 · Healthy, Idiopathic Inflammatory Myopathies
XmAb657
XNCR
Xencor, Inc.
Phase 1Recruiting60Oct 2028Registry ↗
Aug 3, 2026A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthri…
NCT07230353 · Rheumatoid Arthritis
Plamotamab
XNCR
Xencor, Inc.
Phase 1Recruiting68Jun 2028Registry ↗
Aug 3, 2026Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142 · Clear Cell Renal Cell Carcinoma
XmAb819
XNCR
Xencor, Inc.
Phase 1Recruiting307Feb 2027Registry ↗
May 5, 2026XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients Wi…
NCT05005728 · Metastatic Castration-Resistant Prostate Cancer
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib
XNCR
Xencor, Inc.
Phase 2Completed72Jun 10, 2025Registry ↗
Mar 13, 2026Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Pat…
NCT06173505 · Nonsquamous Non-small Cell Lung Cancer
Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carbo…
XNCR
Xencor, Inc.
Phase 1/2Terminated28Dec 24, 2025Registry ↗
Dec 2, 2025Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
NCT06005792 · Psoriasis, Atopic Dermatitis
XmAb27564, Placebo
XNCR
Xencor, Inc.
Phase 1Terminated23Mar 22, 2024Registry ↗
Aug 7, 2025Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With…
NCT05585034 · Head and Neck Squamous Cell Carcinoma, Melanoma Excluding U…
XmAb®808, Keytruda® (pembrolizumab)
XNCR
Xencor, Inc.
Phase 1Completed60May 20, 2025Registry ↗
Feb 7, 2025A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Ma…
NCT05032040 · Ovarian Cancer, Clear Cell Carcinoma
vudalimab
XNCR
Xencor, Inc.
Phase 2Active, not recruiting170Oct 15, 2025Registry ↗
Nov 13, 2024Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressin…
NCT02924402 · B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
XmAb13676
XNCR
Xencor, Inc.
Phase 1Completed154Apr 2024Registry ↗
Aug 23, 2024A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05996445 · Solid Tumors
XmAb662, Keytruda® (pembrolizumab)
XNCR
Xencor, Inc.
Phase 1Terminated7May 21, 2024Registry ↗
Jul 5, 2024A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03752398 · Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
XmAb®23104, Yervoy® (ipilimumab)
XNCR
Xencor, Inc.
Phase 1Completed198Feb 15, 2024Registry ↗
Apr 30, 2024Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Len…
NCT05328102 · Diffuse Large-cell B-cell Lymphoma
Plamotamab, Tafasitamab
XNCR
Xencor, Inc.
Phase 2Terminated3Feb 21, 2023Registry ↗
Apr 20, 2023Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-sta…
NCT04590781 · Merkel Cell Carcinoma, Small Cell Lung Cancer
XmAb18087, XmAb18087 ± Pembrolizumab
XNCR
Xencor, Inc.
Phase 1/2Terminated4Mar 24, 2022Registry ↗
Mar 30, 2023A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advance…
NCT03849469 · Melanoma, Cervical Carcinoma
XmAb®22841, Pembrolizumab (Keytruda®)
XNCR
Xencor, Inc.
Phase 1Completed78Feb 16, 2023Registry ↗
Mar 7, 2023Study Evaluating AMG 424 in Subjects With Multiple Myeloma
NCT03445663 · Relapsed/ Refractory Multiple Myeloma
AMG 424
XNCR
Xencor, Inc.
Phase 1Terminated27Jun 19, 2020Registry ↗
Mar 1, 2023Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
NCT04857866 · Safety in Healthy Volunteers
XmAb27564, Placebo
XNCR
Xencor, Inc.
Phase 1Completed48Nov 10, 2022Registry ↗
Dec 1, 2022A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488 · Melanoma, Breast Carcinoma
XmAb20717
XNCR
Xencor, Inc.
Phase 1Completed150Jun 1, 2022Registry ↗
May 10, 2022A Study of XmAb®18087 in Subjects With NET and GIST
NCT03411915 · Neuroendocrine Tumor, Gastrointestinal Neoplasm
XmAb18087
XNCR
Xencor, Inc.
Phase 1Completed62Oct 26, 2021Registry ↗
Mar 8, 2022PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hemat…
NCT02730312 · Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leuk…
XmAb14045
XNCR
Xencor, Inc.
Phase 1Completed120Sep 2021Registry ↗
Aug 20, 2019A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 · Systemic Lupus Erythematosus
XmAb5871, Placebo to match XmAb5871
XNCR
Xencor, Inc.
Phase 2Completed105Jul 17, 2018Registry ↗
Dec 7, 2018Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease…
NCT02725476 · IgG4-RD
XmAb5871
XNCR
Xencor, Inc.
Phase 2Completed20Dec 2017Registry ↗
Dec 8, 2017XmAb5871 Bioavailability Study
NCT02867098 · Healthy Volunteers
XmAb5871
XNCR
Xencor, Inc.
Phase 1Completed50Oct 21, 2016Registry ↗
Jul 11, 2017Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
NCT02881853 · Healthy Volunteers, Atopic Disease
XmAb7195, Placebo
XNCR
Xencor, Inc.
Phase 1Completed57Feb 24, 2017Registry ↗
Jan 24, 2017Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History…
NCT02148744 · Allergic Rhinitis, Allergic Conjunctivitis
XmAb7195, Placebo
XNCR
Xencor, Inc.
Phase 1Completed72Sep 21, 2015Registry ↗

28 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:48 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances